Alexion Looks To Broaden Complement Inhibitor Market With Next-Generation Ultomiris

 
• By John Davis
Stepping stones
Alexion is taking steps to add further indications to its next-generation complement inhibitor • Source: Shutterstock

More from Blood and Clotting

More from Therapeutic Category